Ascendis Pharma A/S (NASDAQ:ASND) Given “Outperform” Rating at Wedbush

Ascendis Pharma A/S (NASDAQ:ASND)‘s stock had its “outperform” rating reiterated by Wedbush in a note issued to investors on Thursday,Benzinga reports. They presently have a $273.00 target price on the biotechnology company’s stock. Wedbush’s price target would suggest a potential upside of 14.29% from the stock’s current price.

Several other research analysts have also commented on ASND. Cantor Fitzgerald restated an “overweight” rating and set a $300.00 price target on shares of Ascendis Pharma A/S in a research note on Monday, March 2nd. Barclays initiated coverage on shares of Ascendis Pharma A/S in a research note on Tuesday, January 27th. They set an “overweight” rating and a $342.00 price target on the stock. Stifel Nicolaus set a $332.00 price target on shares of Ascendis Pharma A/S in a research note on Wednesday, March 4th. Wolfe Research restated an “outperform” rating and set a $260.00 price target on shares of Ascendis Pharma A/S in a research note on Monday, March 2nd. Finally, Wells Fargo & Company increased their price target on shares of Ascendis Pharma A/S from $322.00 to $330.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 20th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $289.89.

Ascendis Pharma A/S Stock Performance

Ascendis Pharma A/S stock opened at $238.87 on Thursday. The firm’s 50 day moving average price is $226.87 and its two-hundred day moving average price is $214.50. Ascendis Pharma A/S has a twelve month low of $132.52 and a twelve month high of $248.60. The firm has a market cap of $14.89 billion, a PE ratio of -54.24 and a beta of 0.49.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings results on Thursday, February 12th. The biotechnology company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.58). The firm had revenue of $290.38 million for the quarter, compared to the consensus estimate of $285.35 million. Equities analysts anticipate that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Corient Private Wealth LLC grew its stake in Ascendis Pharma A/S by 17.7% in the 4th quarter. Corient Private Wealth LLC now owns 3,393 shares of the biotechnology company’s stock valued at $724,000 after buying an additional 510 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in Ascendis Pharma A/S in the 4th quarter valued at $42,000. Seven Fleet Capital Management LP acquired a new position in Ascendis Pharma A/S in the 4th quarter valued at $1,209,000. Dorsey Wright & Associates boosted its holdings in Ascendis Pharma A/S by 3.2% in the 4th quarter. Dorsey Wright & Associates now owns 8,504 shares of the biotechnology company’s stock valued at $1,813,000 after purchasing an additional 263 shares during the period. Finally, Empowered Funds LLC boosted its holdings in Ascendis Pharma A/S by 1.7% in the 4th quarter. Empowered Funds LLC now owns 36,697 shares of the biotechnology company’s stock valued at $7,825,000 after purchasing an additional 620 shares during the period.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.